Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate
June 05, 2024 09:00 ET
|
Osteal Therapeutics
Osteal Therapeutics secured $50M in Series D financing led by Zimmer Biomet. The funds will advance VT-X7, a treatment for periprosthetic joint infection.
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
August 28, 2023 08:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023 08:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
June 27, 2023 08:30 ET
|
ContraFect Corporation
YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
April 26, 2023 09:00 ET
|
ContraFect Corporation
YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
April 03, 2023 08:30 ET
|
ContraFect Corporation
YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update
March 31, 2023 08:30 ET
|
ContraFect Corporation
YONKERS, N.Y., March 31, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase
December 19, 2022 16:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections
November 28, 2022 08:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 08:00 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...